An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTA Given Concomitantly With PedvaxHIB and Infanrix in Healthy Children 15 Months of Age.

Trial Profile

An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of VAQTA Given Concomitantly With PedvaxHIB and Infanrix in Healthy Children 15 Months of Age.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Hepatitis A vaccine inactivated (Primary) ; DTaP vaccine; Hib vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis A; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 23 Oct 2011 Primary endpoint 'Geometric-mean-antibody-titre' has been met.
    • 23 Oct 2011 Primary endpoint 'Antibody-levels' has been met.
    • 23 Oct 2011 Results presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top